Follow
IRRAS AB
Nasdaq First North Sweden (Sweden)
IRRAS AB is a commercial-stage medical technology company. The company develops and sells medical equipment for the treatment of brain pathologies, including a device for drainage and monitoring of intracranial pressure. Its product IRRAflow CNS System combines an External Drainage System, an ICP Monitor and an Occlusion Solution Mechanism into a single, integrated device. It is easy to operate and provides a safe and effective system for intracranial fluid evacuation.
Sector:
HEALTH CARE
>
Medical Devices
New issue
Price
5.80 SEK
Subscription period
26 Mar - 09 Apr 2020
View Details
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
IRRAS
SE0008321202
Nasdaq First North Sweden
Sweden (SE)
Details of share in IRRAS AB with ticker IRRAS
Status
Active
Order book id
Amount of instruments
28 817 974
Par value
0.0300
Market cap
Currency
SEK
Segment
First North Premier
First trading date
22 Nov 2017
Terms
Type
Price
Pre-money valuation
Time
IPO
774.8M SEK
14 Nov - 20 Nov 2017
IPO in IRRAS AB
Market
Nasdaq First North Sweden
Subscription period
14 Nov - 20 Nov 2017
Subscription price
Price per share
Target to raise
350 000 000 SEK
Types
Pre-money valuation
774 800 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
First trading date
22 Nov 2017
Issue terms
Type
Price
Pre-money valuation
Time
New issue
22.00 SEK
528.4M SEK
22 May - 22 May 2019
Share issue in IRRAS AB
Market
Nasdaq First North Sweden
Subscription period
22 May - 22 May 2019
Subscription price
Price per share
22.00 SEK
Target to raise
105 600 000 SEK
Types
Share issue
Pre-money valuation
528 400 000 SEK
Subscription block size
Minimum subscription
Record date
Offer status
Closed
Listing status
Listed
Issue terms
Directed new issue to Swedish and international institutional investors, via an accelerated bookbuilding procedure. Carnegie Investment Bank AB and Pareto Securities AB are Joint Bookrunners.
Type
Price
Pre-money valuation
Time
New issue
5.80 SEK
167.43M SEK
26 Mar - 09 Apr 2020
Share issue in IRRAS AB
Market
Nasdaq First North Sweden
Subscription period
26 Mar - 09 Apr 2020
Subscription price
5.80 SEK
Price per share
5.80 SEK
Target to raise
217 000 000 SEK
Types
Share issue
Pre-money valuation
167 430 000 SEK
Subscription block size
Minimum subscription
Record date
24 Mar 2020
Offer status
Active
Listing status
Listed
 
Issue terms
For each share held on the record date, shareholders will receive one (1) subscription right. Ten (10) subscription rights entitles to subscription for thirteen (13) new shares. Application for subscription without subscription rights will also be possible.
Comments for offer & related information
The company shall issue a maximum of 37 463 366 shares. IRRAS has received subscription undertakings corresponding to approximately 25 percent of the Rights Issue from existing shareholders. The Company’s larger shareholders Lexington Holding Assets Ltd and Bacara Holdings Limited, the Fourth Swedish National Pension Fund and Carl-Olof and Jenz Hamrin’s Foundation all have, in addition to entering into subscribing undertakings for their pro rata share, also committed to underwrite an amount of SEK 129 million in the Rights Issue, subject to customary conditions. The remaining part of the Rights Issue is underwritten by several external investors.
People
Number of Employees
33 people
Kleanthis G. Xanthopoulos
CEO
Anders P. Wiklund
Chairman of the board
Anders P. Wiklund
Board member
Saeid Esmaeilzadeh
Board member
Marios Fotiadis
Board member
Eva Nilsagård
Board member
Anita Tollstadius
Board member
Kleanthis G. Xanthopoulos
Board member
Company Details
Sector
HEALTH CARE

Address
Box 160
Zip code
101 23
City/district
Stockholm
Country
Sweden (SE)
Registration number
556872-7134
LEI code
549300EKKVQN2J25MJ59
First trade date
22 Nov 2017
Registration date
24 Nov 2011
Short name
IRRAS

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date